The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)

doi:10.1017/9781108623872.015

Case 15: - The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)

Published online by Cambridge University Press: 03 April 2024

Nevena Radonjić and

Elena Cappello

Edited by

Nevena V. Radonjić ,

Thomas L. Schwartz and

Stephen M. Stahl

Show author details

Nevena V. Radonjić: Affiliation:
State University of New York Upstate Medical University
Thomas L. Schwartz: Affiliation:
State University of New York Upstate Medical University
Stephen M. Stahl: Affiliation:
University of California, San Diego

Book contents

Get access

Summary

Which medication is least likely to precipitate a myasthenic crisis in a patient with MG?

Keywords

myasthenia gravis bipolar disorder borderline personality disorder lamotrigine (Lamictal)lithium (Eskalith)carbamazepine (Tegretol)quetiapine (Seroquel)

Type: Chapter
Information: Case Studies: Stahl's Essential Psychopharmacology , pp. 249 - 264

DOI: https://doi.org/10.1017/9781108623872.015 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Abualkhair, L, Almaghrabi, A, Al Edrees, N, et al. Unmasking of myasthenia gravis after introduction of oral risperidone in a schizophrenic Saudi male: a case report. Cureus 2021; 13:e20541Google Scholar

Blum, N, St John, D, Pfohl, B, et al. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry 2008; 165:468–78CrossRef Google Scholar PubMed

Bozzatello, P, Rocca, P, Baldassarri, L, et al. The role of trauma in early onset borderline personality disorder: a biopsychosocial perspective. Front Psychiatry 2021; 12; https://doi.org/10.3389/fpsyt.2021.721361 CrossRef Google Scholar PubMed

Cattane, N, Rossi, R, Lanfredi, M, et al. Borderline personality disorder and childhood trauma: exploring the affected biological systems and mechanisms. BMC Psychiatry 2017; 17:221CrossRef Google Scholar PubMed

Choi-Kain, LW, Albert, EB, Gunderson, JG. Evidence-based treatments for borderline personality disorder: implementation, integration, and Stepped Care. Harv Rev Psychiatry 2016; 24:342–56CrossRef Google Scholar PubMed

Choi-Kain, LW, Finch, EF, Masland, SR, et al. What works in the treatment of borderline personality disorder. Curr Behav Neurosci Rep 2017; 4:21–30CrossRef Google Scholar PubMed

Crawford, MJ, MacLaren, T, Reilly, JG. Are mood stabilisers helpful in treatment of borderline personality disorder? BMJ 2014; 349:g5378CrossRef Google Scholar PubMed

Goldberg, JF. Personality Disorders and Traits. Cambridge: Cambridge University Press, 2021.Google Scholar

Goodman, M, Carpenter, D, Tang, CY, et al. Dialectical behavior therapy alters emotion regulation and amygdala activity in patients with borderline personality disorder. J Psychiatr Res 2014; 57:108–16CrossRef Google Scholar PubMed

Gregory, RJ, Remen, AL. A manual-based psychodynamic therapy for treatment-resistant borderline personality disorder. Psychotherapy (Chic) 2008; 45:15–27CrossRef Google Scholar PubMed

Hancock-Johnson, E, Griffiths, C, Picchioni, M. A focused systematic review of pharmacological treatment for borderline personality disorder. CNS Drugs 2017; 31:345–56CrossRef Google Scholar PubMed

Jordan, H, Ortiz, N. Management of insomnia and anxiety in myasthenia gravis. J Neuropsychiatry Clin Neurosci 2019; 31:386–91CrossRef Google Scholar PubMed

Lis, E, Greenfield, B, Henry, M, et al. Neuroimaging and genetics of borderline personality disorder: a review. J Psychiatry Neurosci 2007; 32:162–73Google Scholar PubMed

Martín-Blanco, A, Ferrer, M, Soler, J, et al. Association between methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity in borderline personality disorder. J Psychiatr Res 2014; 57:34–40CrossRef Google Scholar PubMed

McGowan, PO, Sasaki, A, D’Alessio, AC, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009; 12:342–8CrossRef Google Scholar PubMed

Oldham, JM, Glen Gabbard, CO, Goin, MK, et al. Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. Washington, DC: American Psychiatric Association 2010Google Scholar

Paris, J. Suicidality in borderline personality disorder. Medicina 2019; 55:223CrossRef Google Scholar PubMed

Perez-Rodriguez, MM, Bulbena-Cabré, A, Bassir Nia, A, et al. The neurobiology of borderline personality disorder. Psychiatr Clin North Am 2018; 41:633–50CrossRef Google Scholar PubMed

Radtke, KM, Schauer, M, Gunter, HM, et al. Epigenetic modifications of the glucocorticoid receptor gene are associated with the vulnerability to psychopathology in childhood maltreatment. Transl Psychiatry 2015; 5:e571CrossRef Google Scholar PubMed

Sheikh, S, Alvi, U, Soliven, B, et al. Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med 2021; 10:1537CrossRef Google Scholar PubMed

Skoglund, C, Tiger, A, Rück, C, et al. Familial risk and heritability of diagnosed borderline personality disorder: a register study of the Swedish population. Mol Psychiatry 2021; 26:999–1008CrossRef Google Scholar PubMed

Stahl, SM. Mood Disorders and the Neurotransmitter Networks Norepinephrine and γ-Aminobutyric Acid (GABA), 5. Cambridge: Cambridge University Press, 2021, 244–82Google Scholar

Starcevic, V, Janca, A. Pharmacotherapy of borderline personality disorder: replacing confusion with prudent pragmatism. Curr Opin Psychiatry 2018; 31:69–73Google Scholar PubMed

Taubner, S, Volkert, J. Evidence-based psychodynamic therapies for the treatment of patients with borderline personality disorder. Clin Psychol Eur 2019; 1:1–20CrossRef Google Scholar

Thomas, N, Gurvich, C, Kulkarni, J. Borderline personality disorder, trauma, and the hypothalamus–pituitary–adrenal axis. Neuropsychiatr Dis Treat 2019; 15:2601–12CrossRef Google Scholar PubMed

Watanabe, Y, Hongo, S. Long-term efficacy and safety of lamotrigine for all types of bipolar disorder. Neuropsychiatr Dis Treat 2017; 13:843–54CrossRef Google Scholar PubMed

Witt, SH, Streit, F, Jungkunz, M, et al. Genome-wide association study of borderline personality disorder reveals genetic overlap with bipolar disorder, major depression and schizophrenia. Transl Psychiatry 2017; 7:e1155CrossRef Google Scholar PubMed

Yadav, D. Prescribing in borderline personality disorder – the clinical guidelines. Prog Neurol Psychiatry 2020; 24:25–30CrossRef Google Scholar

Zhang, TY, Labonté, B, Wen, XL, et al. Epigenetic mechanisms for the early environmental regulation of hippocampal glucocorticoid receptor gene expression in rodents and humans. Neuropsychopharmacology 2013; 38:111–23Google Scholar